Chris Schott
Stock Analyst at JP Morgan
(3.98)
# 534
Out of 5,182 analysts
155
Total ratings
60.75%
Success rate
6.89%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $225 → $250 | $240.96 | +3.75% | 1 | Mar 5, 2026 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $22.77 | +22.97% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $921.35 | +41.10% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $758.73 | +25.21% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $29.68 | +17.92% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $10.56 | +70.45% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $6.05 | +98.35% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $117.94 | +69.58% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $576.24 | +34.49% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $205.45 | +26.55% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $145 → $150 | $139.44 | +7.57% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $12.39 | +12.99% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $169.30 | +3.37% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $47.54 | -11.65% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $341.92 | -21.03% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $27.89 | +21.93% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $120.49 | +3.74% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $13.38 | +4.63% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.70 | +547.06% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.38 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $58.93 | +32.37% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.17 | +554,482.60% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.12 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.43 | +122.92% | 3 | Nov 2, 2018 |
Johnson & Johnson
Mar 5, 2026
Maintains: Neutral
Price Target: $225 → $250
Current: $240.96
Upside: +3.75%
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $22.77
Upside: +22.97%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $921.35
Upside: +41.10%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $758.73
Upside: +25.21%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $29.68
Upside: +17.92%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $10.56
Upside: +70.45%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $6.05
Upside: +98.35%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $117.94
Upside: +69.58%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $576.24
Upside: +34.49%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $205.45
Upside: +26.55%
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $139.44
Upside: +7.57%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.39
Upside: +12.99%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $169.30
Upside: +3.37%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $47.54
Upside: -11.65%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $341.92
Upside: -21.03%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $27.89
Upside: +21.93%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $120.49
Upside: +3.74%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $13.38
Upside: +4.63%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.70
Upside: +547.06%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.38
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $58.93
Upside: +32.37%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.17
Upside: +554,482.60%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.12
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.43
Upside: +122.92%